RBC Bioscience

RBC Bioscience Net Debt

The Net Debt of RBC Bioscience (6848.TWO) as of Oct 23, 2026 is 397.34 M TWD. In the previous year, Net Debt was 406.47 M TWD — a change of -2.25% (lower).

Net Debt

397.34 MTWD

YoY

-2.25%

Last updated:

Net Debt of RBC Bioscience is 2024 397.34 M TWD. Net Debt of RBC Bioscience was 2023 406.47 M TWD. It decreases by -2.25% lower compared to the previous year.

The RBC Bioscience Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
25.38 M TWD
Jan 1, 2019
51.57 M TWD
Jan 1, 2020
-63.48 M TWD
Jan 1, 2021
384.51 M TWD
Jan 1, 2022
405.11 M TWD
Jan 1, 2023
406.47 M TWD
Jan 1, 2024
397.34 M TWD
The RBC Bioscience Net Debt history
YEARNet DebtYoY
397.34 MTWD-2.25%
406.47 MTWD+0.34%
405.11 MTWD+5.36%
384.51 MTWD-705.72%
-63.48 MTWD-223.09%
51.57 MTWD+103.24%
25.38 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Net Debt of RBC Bioscience is 397.34 M TWD in 2024.

Net Debt of RBC Bioscience changed from 406.47 M TWD to 397.34 M TWD, representing a -2.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's RBC Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RBC Bioscience

All Key Metrics — RBC Bioscience